Trimetazidine reduces oxidative stress in cardiac surgery

Simple item page
dc.contributor.authorIskesen I.
dc.contributor.authorSaribulbul O.
dc.contributor.authorCerrahoglu M.
dc.contributor.authorVar A.
dc.contributor.authorNazli Y.
dc.contributor.authorSirin H.
dc.date.accessioned2024-07-22T08:23:13Z
dc.date.available2024-07-22T08:23:13Z
dc.date.issued2006
dc.description.abstractBackground: Trimetazidine is an anti-ischemic agent that is used to treat angina and it has cardioprotective effects without inducing any significant hemodynamic changes. It inhibits the long-chain mitochondrial 3-ketoacyl coenzyme A thiolase enzyme in the myocyte and can improve cardiac mitochondrial metabolism, as well as scavenge free radicals. The aim of this double-blind prospective randomized study was to investigate the effect of preoperative use of trimetazidine on the reduction of oxidative stress during coronary artery bypass grafting (CABG) under cardiopulmonary bypass (CPB). Methods and Results: The study group (group T) and the control group (group C) each comprised 12 patients. Pretreatment began 2 weeks before CABG with trimetazidine (60 mg/day po); the control group did not receive any medication. Serial blood samples were collected before and after CPB for measurement of the serum concentrations of these major endogenous antioxidant enzyme systems, which are markers for oxidative degradation of the cellular membranes; postoperative levels were significantly different between the groups (p<0.05). There were no significant difference in hemodynamic values. Conclusion: The findings suggest that pretreatment with trimetazidine alleviates malondialdehyde production and preserves endogenous antioxidant capacity during CABG with CPB and cardioplegic arrest.
dc.identifier.DOI-ID10.1253/circj.70.1169
dc.identifier.issn13474820
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/19442
dc.language.isoEnglish
dc.rightsAll Open Access; Bronze Open Access
dc.subjectAged
dc.subjectAntioxidants
dc.subjectCoronary Artery Bypass
dc.subjectFemale
dc.subjectHeart Arrest, Induced
dc.subjectHumans
dc.subjectMale
dc.subjectMalondialdehyde
dc.subjectMiddle Aged
dc.subjectOxidative Stress
dc.subjectTrimetazidine
dc.subjectVasodilator Agents
dc.subjectantioxidant
dc.subjectglutathione peroxidase
dc.subjectmalonaldehyde
dc.subjectsuperoxide dismutase
dc.subjecttrimetazidine
dc.subjectadult
dc.subjectaged
dc.subjectarticle
dc.subjectblood sampling
dc.subjectcardioplegia
dc.subjectcardiopulmonary bypass
dc.subjectcell membrane
dc.subjectclinical article
dc.subjectclinical trial
dc.subjectcontrolled clinical trial
dc.subjectcontrolled study
dc.subjectcoronary artery bypass graft
dc.subjectdouble blind procedure
dc.subjectdrug mechanism
dc.subjectheart surgery
dc.subjecthemodynamics
dc.subjecthuman
dc.subjectlipid peroxidation
dc.subjectoxidative stress
dc.subjectpreoperative treatment
dc.subjectprospective study
dc.subjectrandomized controlled trial
dc.titleTrimetazidine reduces oxidative stress in cardiac surgery
dc.typeArticle

Files

Collections

Scopus Koleksiyonu